



## Antibacterial Resistance and Novel Therapeutic Strategies

Guest Editors:

**Dr. Sílvia A. Sousa**

**Dr. Norouzitallab Parisa**

**Dr. Ashok Aspatwar**

**Dr. Sonia Martinez**

Deadline for manuscript  
submissions:

**closed (15 December 2023)**

### Message from the Guest Editors

Bacterial human infectious diseases remains a serious threat to public health worldwide. In addition, the emergence of bacterial resistance to the clinically in-use antimicrobials lowers the efficacy of available prevention and treatment measures, leading to extended hospitalization periods and causing a severe financial burden to healthcare systems worldwide. Development of novel antibiotics with chemical characteristics distinct from those already available commercially is urgently required. Additionally, to avoid antimicrobial resistance, antibiotics with novel modes of action or interacting targets distinct from those which are clinically in use will be the most interesting to explore. At the same time, more studies are needed about the molecular pathways involved in the formation and survival of persisters, in order to develop new therapeutic strategies to eliminate them.

In this Special Issue of *Antibiotics*, we invite authors to submit articles concerning any aspects related to the development of new antibacterial agents and/or their mechanism of action. Also welcome studies about bacterial resistance to antibiotics and antibiotic persisters.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

## Contact Us

---

*Antibiotics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/antibiotics  
antibiotics@mdpi.com  
X@antibioticsmdpi